Form 4: Repare Therapeutics EVP, CFO Steve Forte Granted 500,000 Stock Options

Steve Forte, EVP and CFO of Repare Therapeutics, was granted 500,000 employee stock options on April 2, 2025, vesting fully on April 2, 2026.

Summary

• On April 2, 2025, Steve Forte, the EVP and Chief Financial Officer of Repare Therapeutics Inc., was granted 500,000 employee stock options.
• The options have an exercise price of $1.07.
• The options will vest in full on April 2, 2026, contingent upon Forte's continued service with the company.
• The options expire on April 1, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns management's interests with shareholders.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to contribute to the company's success.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry, often benchmarked against peer companies of similar size and stage of development.
• Companies like Relay Therapeutics, Black Diamond Therapeutics, and Revolution Medicines also utilize stock options as part of their executive compensation strategy.

Stakeholder Impact

• Shareholders: The grant of stock options aligns the CFO's interests with those of the shareholders.
• Employees: The grant could have a positive impact on employee morale as it shows the company is investing in its leadership.

Key Dates

Keywords

stock options, Repare Therapeutics, Steve Forte, EVP, CFO, Form 4, beneficial ownership, equity securities, vesting